share_log

Piper Sandler Maintains Overweight on Supernus Pharmaceuticals, Lowers Price Target to $42

Piper Sandler Maintains Overweight on Supernus Pharmaceuticals, Lowers Price Target to $42

派珀·桑德勒维持对Supernus Pharmicals的增持,将目标股价下调至42美元
Benzinga ·  2023/10/25 15:38

Piper Sandler analyst David Amsellem maintains Supernus Pharmaceuticals (NASDAQ:SUPN) with a Overweight and lowers the price target from $43 to $42.

派珀·桑德勒分析师David·安塞勒姆维持对纳斯达克(Supernus PharmPharmticals)的增持,并将目标价从43美元下调至42美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发